Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2

Status

Unknown 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Breast Neoplasms 1889Carcinoma, Non-Small-Cell Lung 1350Prostatic Neoplasms 980Colorectal Neoplasms 851Multiple Myeloma 741Leukemia, Myeloid, Acute 725Neoplasms 691Lung Neoplasms 680Neoplasm Metastasis 642Lymphoma 579Carcinoma, Hepatocellular 571Pancreatic Neoplasms 567Stomach Neoplasms 523Leukemia 511Recurrence 493Leukemia, Lymphocytic, Chronic, B-Cell 459Precursor Cell Lymphoblastic Leukemia-Lymphoma 452Melanoma 451Lymphoma, Non-Hodgkin 443Ovarian Neoplasms 426Lymphoma, Large B-Cell, Diffuse 423Squamous Cell Carcinoma of Head and Neck 416Myelodysplastic Syndromes 416Head and Neck Neoplasms 404Brain Neoplasms 403Rectal Neoplasms 397Glioblastoma 375Carcinoma, Renal Cell 350Hodgkin Disease 338Esophageal Neoplasms 337

Interventions

disitamab vedotin 2Trastuzumab 2Tegafur 2tislelizumab 1S 1 (combination) 1Oxaliplatin 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × OTHER × HER2-positive Gastric Cancer × Clear all
NCT05586061 2025-02-07

RCTS

Qilu Hospital of Shandong University

Phase 2 Active not recruiting
55 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06492317 2024-07-09

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
20 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05311189 2022-04-05

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

Shanghai Zhongshan Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05270889 2022-03-08

Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

Yonsei University

Phase 2 Unknown
50 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05070598 2021-10-07

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

Shengjing Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡